Why I advocated on Capitol Hill this month for the renewal of the FDA’s Priority Review Voucher program
Opinion: Congress Must Reauthorize FDA Program for Pediatric Rare Diseases Read More »
After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and neurodegenerative disease spaces during the next six months.
5 Neuro Data Readouts to Watch in the Second Half of 2024 Read More »
Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression.
Breaking the Cycle of Inflammation in Parkinson’s Disease Read More »
Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), specializing in biological research reagents and related technical contract research services, has successfully concluded the acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc.
SignalChem Biotech, World Leader in Kinases, Is Now Part of Sino Biological Read More »
La importancia de comprender las numerosas opciones farmacológicas actuales como así también saber valorar en el consultorio las condiciones y el estilo de vida individual
The FDA said 15 injuries have been tied to the use of three models of Megadyne patient return electrodes.
J&J limits use of Megadyne electrodes due to burn risk Read More »
The Center for Devices and Radiological Health is aiming to help companies manage challenges such as inaccurate participant reports of drug use.
FDA finalizes guidance on studying opioid use disorder treatments Read More »
The Department of Justice investigation follows a multi-year international probe into Steward’s deal to improve three hospitals in Malta.
Steward Health Care under federal investigation for fraud and corruption Read More »
The startup claims companies that choose its device over Illumina’s sequencer can save almost $1.5 million in three years.
Element raises $277M to challenge Illumina in sequencing market Read More »
The Federal Trade Commission criticized the business practices of pharmacy benefit managers this week, but drugmakers are also at fault for the high costs of medicines.
PBMs and Big Pharma Play Blame Game for Inflated Prescription Drug Prices Read More »
